title: Stroke thrombolysis: where are we and where are we going?
abstract: Stroke is an important cause of death and disability throughout the world. Most strokes are ischaemic, caused by thrombotic or embolic occlusion of blood vessels. The advent of thrombolysis for acute ischaemic stroke has revolutionised the treatment of acute stroke in the developed world. The benefit of thrombolysis in acute stroke is very time-dependent, with the greatest benefit achieved when administered within 90 minutes of ictus, but trials demonstrating some benefit up to 4.5, and possibly 6 hours. This has revolutionised stroke treatment, with redesign of clinical pathways to try to ensure patients with suspected stroke reach a hospital with a thrombolysis service as quickly as possible. Clinical stroke services need to ensure that all acute stroke patients can be scanned, treated and admitted to stroke units without delay. Future research needs to address the prevention and better management of complications, such as secondary intracerebral haemorrhage and angioedema. In addition, the evidence base for direct intra-arterial intervention such as thrombectomy needs to be established.
authors.affiliation: The University of Manchester Vascular and Stroke Centre, Manchester Academic Health Science Centre, Salford Royal Hospitals Foundation Trust, UK.
authors.forename: R
authors.initials: R
authors.lastname: Hurford
authors.forename: P J
authors.initials: PJ
authors.lastname: Tyrrell
mesh_terms: D002545:Brain Ischemia; D002543:Cerebral Hemorrhage; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D020521:Stroke; D015912:Thrombolytic Therapy
chemical_list: D005343:Fibrinolytic Agents
keywords: Alteplase; ischaemic stroke; thrombolysis